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ABSTRACT
The functional integrity of the endothelium is
essential for vascular health. In addition to
maintaining a delicate balance between
vasodilation and vasoconstriction, the
endothelium has numerous other complex roles
involved in the maintenance of vascular
homeostasis. Chronic exposure to cardiovascu-
lar risk factors and oxidative stress results in an
imbalance in these functions, creating an envi-
ronment that favors reduced vasodilation and a
proinflammatory and prothrombic state. The
involvement of endothelial dysfunction in all
stages of the cardiovascular continuum makes it
an important target for treatment. One of the
major endothelial-derived factors involved in
the maintenance of endothelial function is
nitric oxide (NO). Angiotensin-converting
enzyme (ACE) inhibitors increase NO produc-
tion both directly and indirectly by preventing
production of angiotensin II (which diminishes
NO production) and inhibiting the degradation
of bradykinin (which stimulates local release of
NO). Among the ACE inhibitors, perindopril
appears to have the greatest effects on bradyki-
nin and has demonstrated efficacy in a number
of markers of endothelial dysfunction including
arterial stiffness and progression of atheroscle-
rosis. There is also strong evidence supporting
the use of perindopril-based therapy for the
treatment of hypertension and for reducing the
risk of cardiovascular morbidity and mortality
in a wide range of patients across the cardio-
vascular continuum.
Funding: The journal’s Rapid Service Fee was
funded by Servier.
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INTRODUCTION
Cardiovascular diseases (CVD) remain a major
cause of premature death and chronic disability
worldwide [1]. They represent the final stage in
a continuum of cardiovascular risk factors,
subclinical organ damage, and eventually car-
diovascular, cerebrovascular, and renal events
(Fig. 1) [2, 3].
The earliest vascular abnormality in the
continuum is endothelial dysfunction.
Endothelial cells respond to both mechanical
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stimuli and hormonal signals from the circula-
tion to regulate vascular structure and function
by modulating processes such as vascular
smooth muscle cell contraction and prolifera-
tion, platelet function, coagulation, and
monocyte adhesion [4]. Any factors altering the
ability of the endothelium to act as a physical
barrier or metabolize, synthesize, and release
vasoactive mediators will result in endothelial
dysfunction. Endothelial dysfunction is a reli-
able prognostic indicator of cardiovascular
events, independently of traditional cardiovas-
cular risk factors in patients with atherosclerotic
coronary disease or at high cardiovascular risk
[5]. In addition to the correction of cardiovas-
cular risk factors, re-establishing balanced
endothelial function is therefore an important
target for treatment.
Two pathways that play a major role in
endothelial homeostasis, and consequently
endothelial dysfunction, are those of the
renin–angiotensin and bradykinin–nitric oxide
(NO) systems. This review will examine the role
of angiotensin II and bradykinin in the patho-
physiology of endothelial dysfunction, and the
importance of endothelial dysfunction as a tar-
get for the prevention of cardiovascular disease.
Evidence for the protective effects of angio-
tensin-converting enzyme (ACE) inhibitors, via
their actions on both the angiotensin II and
bradykinin pathways, will be presented, with a
particular focus on perindopril as one of the
most widely studied representatives of the ACE-
inhibitor class. This article is based on previ-
ously conducted studies and does not contain
any studies with human participants or animals






Underdisease conditions, including thepresence
of cardiovascular risk factors, the endothelium
undergoes functional and structural alterations
that result in it losing its cardioprotective role
and becoming proatherosclerotic (Fig. 2). A
characteristic feature of endothelial dysfunction
is impaired NO bioavailability [6]. This may be a
consequenceof either reducedNOproductionby
endothelial nitric oxide synthase (eNOS) or
increased breakdown of NO by reactive oxygen
species (ROS) [7, 8]. Following its production and
release by the endothelium, NO diffuses to sur-
rounding tissues where it exerts important car-
diovascular protective effects including
relaxation of media smooth muscle cells, pre-
vention of leukocyte adhesion and migration
into the arterial wall, and prevention of muscle
cell proliferation, platelet adhesion and aggre-
gation, and adhesion molecule expression [7, 8].
Fig. 1 The cardiovascular continuum. MI myocardial infarction, CHF congestive heart failure, ESRD end-stage renal
disease. Adapted from Dzau et al. [2]
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Loss of NO is one of the earliest events that leads
to the onset and progression of oxidative stress in
the vasculature.
Angiotensin II and the Endothelium
Angiotensin II plays a central role in endothelial
dysfunction [9]. In addition to increasing blood
pressure via vasoconstriction, it elicits a number
of adverse effects on the vascular wall, the
majority of which occur through its actions on
the angiotensin II type 1 (AT1) receptor. Ele-
vated levels of endothelial angiotensin II stim-
ulate the generation of ROS responsible for NO
breakdown [10] and reduce eNOS-derived NO
by promoting eNOS uncoupling through
monocyte-dependent S-glutathionylation [11].
Angiotensin II also produces conditions favor-
able for atherogenesis by upregulating
endothelial receptors for oxidized low-density
lipoprotein (OxLDL), stimulating OxLDL
uptake, and enhancing OxLDL-mediated ROS
generation. The resulting oxidative stress pro-
motes vascular smooth muscle cell proliferation
and collagen deposition, leading to thickening
of the vascular media and narrowing of the
vascular lumen. Oxidative stress also damages
the endothelium, leading to endothelial cell
apoptosis [12]. It increases receptors for vascular
endothelial growth factors and matrix metallo-
proteinases, which may account for increased
endothelial permeability and vascular remodel-
ing [13–15]; angiotensin II-induced vascular
remodeling may also occur via activation of the
AT2 receptor [16]. Oxidative stress increases the
expression of plasminogen activator inhibitor
type 1, thereby favoring thrombosis [17], and
cytokines, increasing the adhesiveness of the
endothelium and subsequently the recruitment
and binding of inflammatory cells to the
endothelial surface, leading to inflammation
and thrombosis [14, 15]. When not sufficiently
counterbalanced by the actions of bradykinin,
these molecular effects of angiotensin II result
in endothelial dysfunction.
Bradykinin and the Endothelium
The systemic hemodynamic and localized
endothelial effects of bradykinin are mediated
by bradykinin receptor 1 (B1R) and bradykinin
receptor 2 (B2R). B2R is constitutively and
abundantly expressed in the endothelium,
whereas B1R is expressed at low levels and
upregulated in response to stress such as ische-
mia/reperfusion injury, chronic inflammation,
or diabetes [18, 19]. In endothelial cells, acti-
vation of B2R by bradykinin induces the release
of NO, prostacyclin, endothelium-derived
hyperpolarizing factor (EDHF), and tissue plas-
minogen activator, which exert diverse physio-
logical actions on the cardiovascular system,
including regulation of vascular tone and local
blood flow to organs, coagulation, fibrinolysis,
and water–electrolyte balance [20]. Activation
of B1R also induces NO-mediated vasodilatation
[21]. Experimental studies have demonstrated a
protective role of B2R on cardiovascular func-
tion, as a result of its opposing effects on
angiotensin II AT1 receptor activation [22]. In
direct opposition to angiotensin II, bradykinin
causes vasodilatation, exerts an anti-inflamma-
tory effect, decreases ROS, and has anti-fibri-
nolytic and antithrombotic effects [23].
Bradykinin-induced vasodilation has been
shown to be the result of at least two pathways:
Fig. 2 Oxidative stress and endothelial dysfunction in
cardiovascular diseases. LDL-C low-density lipoprotein
cholesterol, BP blood pressure, NO nitric oxide, ACE
angiotensin-converting enzyme, AngII angiotensin II, SMC
smooth muscle cells. Adapted from Dzau et al. [2]
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bradykinin-induced NO and prostaglandin
release, and the hyperpolarization of the mem-
brane through the EDHF pathway [24, 25]. The
anti-inflammatory effects and reduction in ROS
induced by bradykinin have been shown to be
mediated through the release of NO, a key reg-
ulator of endothelial function. Besides anti-in-
flammation, the release of NO also results in an
anti-apoptotic effect of bradykinin [23].
Vascular fibrinolytic balance, which deter-
mines the formation and degradation of
thrombi, is maintained by the balance between
tissue plasminogen activator (T-PA) and plas-
minogen activator type 1 (PAI-1) [26]. Increases
in PAI-1 and decreases in T-PA are associated
with thrombus formation and are a major risk
factor for the development of cardiovascular
events [27]. Bradykinin has been shown to
increase T-PA concentration independently of
other molecular pathways [28, 29], and conse-
quently has strong anti-thrombotic properties.
ACE INHIBITION
AND ENDOTHELIAL FUNCTION
Rationale for Use in Endothelial
Dysfunction
As endothelial dysfunction promotes
atherosclerosis and cardiovascular events in
patients with cardiovascular risk factors,
improving endothelial function is an important
treatment target. Thus, antihypertensive com-
pounds, beyond their ability to reduce blood
pressure, should ideally have additional prop-
erties that specifically restore endothelial func-
tion. A detailed description of the pleiotropic
properties of available antihypertensive agents
is outside the scope of this article, but diuretics
and b-blockers show little evidence of being
able to improve endothelial dysfunction in
patients with hypertension or coronary artery
disease (CAD). Calcium channel blockers have
been shown to reverse impaired endothelium-
dependent vasodilation, mainly in the micro-
circulation by improving NO bioavailability
[30, 31].
The drugs expected to have the greatest
influence on endothelial dysfunction are the
renin–angiotensin system inhibitors. Both ACE
inhibitors and angiotensin receptor blockers
(ARBs) prevent the action of angiotensin II, ACE
inhibitors by preventing its formation and ARBs
by blocking the actions of angiotensin II at AT1
receptors on bloods vessels and other tissues
such as the heart. By targeting angiotensin-
converting enzymes, ACE inhibitors not only
enhance the availability of NO by inhibiting the
conversion of angiotensin I to angiotensin II,
but also by increasing the availability and pre-
venting the degradation of bradykinin (Fig. 3).
ARBs do not inhibit ACE and therefore do not
increase bradykinin levels via this pathway. In
this respect, it is noteworthy that ACE inhibi-
tors, but not ARBs, have consistently demon-
strated reduced cardiovascular mortality and
all-cause death compared with placebo in a
broad range of hypertensive patients [32–34].
Furthermore, a high proportion of the studies
demonstrating the benefits of ACE inhibitors on
cardiovascular mortality were performed with
perindopril.
Evidence for Target Organ Protection
Endothelial Function
The possibility that ACE inhibitors could
improve endothelial function was initially
raised following reports from experimental
studies that the renin–angiotensin system, and
in particular angiotensin II, plays a major role in
inhibiting NO production and activity, mainly
by inducing ROS generation [35]. However, the
role of angiotensin II is not the only explana-
tion for the efficacy of ACE inhibitors regarding
endothelial function, as the literature suggests a
superiority of ACE inhibitors over ARBs. As
described above, bradykinin also has significant
effects on the endothelium. The ability of ACE
inhibitors to increase bradykinin tissue con-
centration by blocking its degradation is an
important mechanism for vascular protection,
especially in the presence of cardiovascular risk
factors or CAD. In the presence of these risk
factors, chronic overexpression of tissue ACE
disrupts the angiotensin II/bradykinin balance,
increasing levels of angiotensin II and
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decreasing tissue levels of bradykinin, the net
result being endothelial dysfunction.
The involvement of the bradykinin pathway
in endothelial responses to ACE inhibition is
well documented. For example, in the PERTI-
NENT (PERindopril Thrombosis INflammation
ENdothelial dysfunction and neurohormonal
activation Trial) substudy of EUROPA (EURo-
pean trial On reduction of cardiac events with
Perindopril in stable CAD), which included
1200 patients with stable CAD, human umbili-
cal vein endothelial cells (HUVECs) were incu-
bated with serum taken from EUROPA patients
both at baseline and after 1 year of treatment
with either placebo or perindopril 10 mg [36].
Perindopril upregulated eNOS protein activity
by 27% (P\0.05). Furthermore, these changes
were highly correlated with increased plasma
bradykinin levels (P\ 0.05), which were
restored to a normal physiological level similar
to that of healthy volunteers. PERTINENT
showed that perindopril improved endothelial
dysfunction by increasing bradykinin and
reducing angiotensin II levels, thereby restoring
the angiotensin II/bradykinin balance.
The effect of ACE inhibitors on the angio-
tensin II/bradykinin balance varies markedly
among different agents. ACE has two different
catalytic domains, one cleaving angiotensin I,
and the other inactivating bradykinin. ACE
inhibitors have a greater affinity for the brady-
kinin than for the angiotensin I binding site,
supporting the concept that these compounds
are primarily inhibitors of bradykinin degrada-
tion rather than inhibitors of angiotensin II
production [37]. Within the ACE inhibitor class,
perindopril has the highest selectivity for the
bradykinin binding site when comparing ena-
lapril, perindopril, quinapril, ramipril, and
trandolapril [37]. The combination of a lipo-
philic profile, high tissue affinity, and a high
bradykinin/angiotensin I selectivity ratio pro-
vide perindopril with a complete and long-
lasting inhibition of bradykinin degradation,
and may offer a greater physiological impact
compared with other ACE inhibitors [38]. In a
head-to-head trial comparing ramipril, quina-
pril, trandolapril, and enalapril, perindopril
provided the greatest reductions in
lipopolysaccharide-induced endothelial
Fig. 3 ACE inhibitor mode of action in balanced endothelial function
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apoptosis [38]. These results are consistent with
data from the PERTINENT study, which repor-
ted a 31% reduction in apoptosis in HUVECs
from patients treated with perindopril [36].
While apoptosis is a marker of endothelial cell
death, circulating endothelial progenitor cells
(CEPC) are an important marker of endothelial
regeneration [39]. Thus, to completely prevent
endothelial dysfunction, optimal treatment
should not only inhibit inflammation and
apoptosis, but also stimulate CEPC production.
In experimental conditions, perindopril has
been shown to increase the number of CEPCs in
the spontaneously hypertensive rat with hind
limb ischemia, while the ARB losartan had no
effect on the number of CEPCs [40, 41].
Arterial Stiffness
Arterial stiffness of the large vessels is a marker
of subclinical target organ damage and an
independent predictor of future cardiovascular
events and mortality beyond blood pressure
alone [42]. Perindopril has been shown to pro-
duce a blood pressure-independent decrease in
arterial stiffness, suggesting that it is able to
reverse adverse structural remodeling of the
arterial wall. In the DAPHNET study (Diabetes
Artery Perindopril Hypertension Normalization
Excess sTiffness), which was conducted in 57
hypertensive patients with diabetes, increasing
the perindopril dosage from 4 to 8 mg resulted
in significantly higher carotid distensibility and
a significantly lower carotid internal diameter
and Young’s elastic modulus [43]. Stepwise
regression analysis confirmed that these
parameters of carotid stiffness were significantly
associated with the dosage of perindopril, and
not with the 24-h blood pressure.
Stiffening of large vessel walls with age or
disease leads to an increase in central aortic
blood pressure. In the CAFE´ (Conduit Artery
Function Evaluation) substudy of ASCOT-BPLA
(Anglo Scandinavian Cardiac Outcomes Trial,
Blood Pressure Lowering Arm), perindopril and
amlodipine were superior to the combination of
atenolol and bendroflumethiazide in lowering
central blood pressure and pulse pressure,
despite similar reductions in brachial blood
pressure [44], which may account for the better
cardiovascular outcomes observed in the
perindopril/amlodipine arm.
Atherosclerosis
The improvements in functional and structural
vascular alterations observed with perindopril
have also been shown to contribute to the pre-
vention of atherosclerosis. This was demon-
strated in PERSPECTIVE (PERindopril’S
Prospective Effect on Coronary aTherosclerosis
by IntraVascular ultrasound Evaluation) [45], a
substudy of EUROPA, which evaluated the
effect of perindopril on progression of coronary
atherosclerosis by coronary angiography and
intravascular ultrasound. There was no evidence
of CAD progression with either perindopril or
placebo [46], but a post hoc analysis of data
from 118 patients found that the effect of
perindopril on coronary plaque progression/re-
gression was dependent on the degree of calci-
fication [45]. Thus, coronary plaques with no or
little calcium (0–25%) regressed on perindopril,
but did not change on placebo (- 0.33 ± 1.74
vs. - 0.03 ± 1.66, respectively; P = 0.04). Pla-
ques with moderate calcium content (group
25–50%) did not change. Plaques with high
calcium content (group 5–100%) progressed
similarly. The important conclusion of the
study is therefore that noncalcified plaques may
be amenable to regression with perindopril
treatment. PERSPECTIVE is the only study to
have provided evidence for the ability of an ACE
inhibitor to prevent progression of coronary
atherosclerosis in vivo.
Ventricular Remodeling
Left ventricular remodeling in which left ven-
tricular volumes increase leading to a rise in
wall stress and altered contractile function is
recognized as a precursor of cardiovascular
events, particularly heart failure, and a strong
predictor of mortality. The PREAMI (Perindopril
and Remodelling in Elderly with Acute
Myocardial Infarction) study demonstrated that
progressive left ventricular remodeling can
occur in elderly post-myocardial infarction (MI)
patients with preserved left ventricular ejection
fraction (LVEF), and that it is possible to prevent
such remodeling with perindopril 8 mg/day
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[47]. Left ventricular remodeling occurred in
27.7% of perindopril- vs. 51.2% of placebo-





The strong evidence that ACE inhibitors, and in
particular perindopril, provide cardiovascular
protection beyond their blood pressure-lower-
ing effects, benefits patients at all stages of the
cardiovascular continuum. Clinical trials inves-
tigating the effects of perindopril on morbidity
and mortality have demonstrated efficacy in a
wide range of patients at risk of cardiovascular
events, from those with uncomplicated hyper-
tension to those with established cardiovascular
disease (Fig. 4).
Hypertension
The ASCOT trial clarified the role of ACE inhi-
bition in the reduction of cardiovascular events
in patients with hypertension without cardio-
vascular disease. In the blood pressure-lowering
arm of the trial, patients (n = 19,257) at mod-
erate cardiovascular risk were randomized to
amlodipine 5–10 mg (with the addition of
perindopril 4–8 mg as required) or the ß-blocker
atenolol with the addition of diuretic as
required [48]. After a median of 5.5 years,
ASCOT was stopped prematurely because
patients in the amlodipine/perindopril group
showed an 11% reduction in all-cause mortality
(P = 0.0247), compared with the beta-blocker/
diuretic regimen. The mean blood pressure in
the amlodipine/perindopril group was 2.7/
1.9 mmHg lower than in the beta-blocker/di-
uretic group. However, this difference could not
entirely account for the differences in outcome.
The CAFE´ study (n = 2199) was a prespecified
Fig. 4 Clinical trials investigating the effects of perindopril on morbidity and mortality have provided evidence of benefits
throughout the cardiovascular disease continuum
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substudy of ASCOT that evaluated the effects of
the two ASCOT treatment regimens on central
aortic pressure [44]. Despite similar reductions
in brachial artery blood pressure, both central
aortic blood pressure and central aortic pulse
pressure were significantly reduced with
amlodipine/perindopril vs. beta-blocker/di-
uretic (24.3 and 23.0 mmHg, respectively, both
P\ 0.0001). Moreover, central aortic pulse
pressure was significantly associated with an
increased risk of cardiovascular events or pro-
cedures and the development of renal impair-
ment. These findings suggest that central aortic
pressure lowering by perindopril and amlodip-
ine combination therapy disrupts the patho-
physiological continuum, thereby slowing
progression to the cardiovascular continuum in
hypertensive patients. The results of the ASCOT
Legacy study, which followed UK participants
from the original ASCOT trial for a median of
16 years, confirmed the long-term beneficial
effects on mortality of antihypertensive treat-
ment with an amlodipine/perindopril treat-
ment regimen [49]. In the 3975 UK patients in
the blood pressure-lowering arm, there were
fewer cardiovascular deaths [adjusted hazard
ration (HR) 0.79, 0.67–0.93, P = 0.0046] among
those assigned to amlodipine/perindopril-based
treatment compared with atenolol/diuretic-
based treatment (P = 0.022).
Type 2 Diabetes
In patients with diabetes, the ADVANCE (Ac-
tion in Diabetes and Vascular disease: PreterAx
and DiamicroN-MR Controlled Evaluation)
study evaluated the clinical benefits of back-
ground blood pressure lowering with a fixed
combination of perindopril and indapamide on
top of standard management in a cohort of
11,140 patients [41, 50]. Over a mean follow-up
of 4.3 years, treatment with perindopril/inda-
pamide fixed combination reduced the inci-
dence of the composite primary endpoint of
macrovascular (non-fatal stroke, non-fatal MI,
and cardiovascular death) and microvascular
(new or worsening nephropathy and retinopa-
thy) events by 9% vs. placebo (P\ 0.05). Car-
diovascular and all-cause mortality were also
reduced by 18% and 14%, respectively (both
P\ 0.05). The beneficial effects of fixed combi-
nation of perindopril and indapamide on the
primary endpoint were similar in the hyper-
tensive and non-hypertensive patients in
ADVANCE [50].
Coronary Artery Disease
CAD is a consequence of endothelial dysfunc-
tion and atherosclerosis. The findings of the
EUROPA trial provided clear evidence for the
efficacy of perindopril in secondary prevention
in patients with stable CAD. Patients with doc-
umented evidence of CAD, but without
uncontrolled hypertension or heart failure
(n = 12,218), were randomly allocated to either
perindopril or placebo on top of other standard
preventative therapies (beta-blockers, lipid-
lowering agents, and antiplatelet agents). After
a mean follow-up of 4.2 years, there was a sig-
nificant 20% reduction in the primary endpoint
(cardiovascular mortality, non-fatal MI, or
resuscitated cardiac arrest) in favor of perindo-
pril (P\0.001) [51, 52]. As described previ-
ously, the EUROPA findings may reflect the
restorative action of perindopril on endothelial
function. In the PERTINENT substudy of
EUROPA, perindopril was found to reduce the
rate of endothelial cell apoptosis by 31%
(P\0.05) [36, 38], an effect that could con-
tribute, at least in part, to explaining the results
of the main EUROPA study.
Stroke
The PROGRESS (Perindopril pROtection aGainst
REcurrent Stroke Study) was the first large-scale
study to investigate the role of ACE inhibition
in secondary prevention of stroke in patients
with a history of stroke or transient ischemic
attack. Patients (n = 6105) were randomized to
active treatment (perindopril 4 mg/day plus the
addition of indapamide at the discretion of the
physician) or placebo. There were no blood
pressure entry criteria, although subjects with
uncontrolled hypertension could receive anti-
hypertensive agents other than an ACE inhi-
bitor. After a mean follow-up of 3.9 years, the
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relative risk of stroke was reduced by 28% in the
perindopril-based regimen vs. placebo
(P = 0.0001). Perindopril was also associated
with a 27% reduction in major cardiovascular
events (non-fatal MI or death from cardiovas-
cular disease) and a 38% reduction in non-fatal
MI [53, 54].
Myocardial Infarction
The PREAMI trial was designed to evaluate the
hypothesis that ACE inhibition in older patients
with acute MI and preserved LVEF would
attenuate left ventricular remodeling and
reduce the occurrence of heart failure and death
[47]. A total of 1252 patients 65 years or older
with a LVEF C 40% and recent acute MI were
randomized to perindopril 8 mg/day or placebo
for 12 months. Ventricular remodeling occurred
in 126 (28%) patients in the perindopril group
and in 226 (51%) patients in the placebo group.
At the end of the study, the composite primary
endpoint of death, hospitalization for heart
failure, and left ventricular remodeling showed
a relative risk reduction of 38% in favor of
perindopril (P\ 0.001) [47].
Heart Failure
Heart failure represents one of the final stages of
the cardiovascular continuum, but successful
management can still improve prognosis. The
PEP-CHF (Perindopril in Elderly People with
Chronic Heart Failure) trial was designed to
improve understanding of the effects of ACE
inhibition in diastolic heart failure. Patients
aged[70 years diagnosed with diastolic heart
failure (n = 870) and preserved LVEF received
either perindopril 2 mg/day or placebo, on top
of standard management [55]. After 1 year, the
event rate was lower than expected and reduced
the statistical power of the study, but perindo-
pril still showed a strong tendency to reduce the
primary endpoint (all-cause mortality, unplan-
ned heart failure-related hospitalization with a
minimum follow-up of 1 year) with a relative
risk reduction of 31% (P = 0.055).
IMPLICATIONS FOR CLINICAL
PRACTICE
Endothelial dysfunction is characterized by a
shift in the balance of the endothelial functions
that maintain vascular homeostasis to one that
favors reduced vasodilation, and a proinflam-
matory and prothrombic state. It is observed
from the earliest stages of the cardiovascular
disease continuum and its effects are cumula-
tive, worsening endothelial dysfunction associ-
ated with progressive vascular damage. An
important priority in cardiovascular disease
prevention is therefore to correct or reduce the
actions of the impaired endothelium that are
driving the cardiovascular continuum. This will
involve reducing or eliminating the triggering
risk factors for endothelial dysfunction as well
as attempting to restore balance to the dis-
rupted endothelial homeostasis.
Certain cardiovascular drugs have pleiotropic
effects that improve endothelial function inde-
pendently of their primary indication. For
example, it is well known that statins exert ben-
eficial effects independent of cholesterol lower-
ing, decreasing inflammation and
thrombogenesis and stabilizing the atheroscle-
rotic plaque. Among the antihypertensive
agents, the ACE inhibitors appear to have the
strongest effects on endothelial dysfunction. In
addition to correcting elevated blood pressure, a
triggering risk factor for the condition, they are
also able to increase levels of NO by inhibiting
theproductionof angiotensin II and inparticular
by inhibiting the degradation of bradykinin.
Among theACE inhibitors, perindopril exerts the
greatest selectivity for the bradykinin binding
site. It also has good lipid solubility for enhanced
tissue penetration anda longhalf-life resulting in
excellentACE inhibition throughout a24-hcycle
after a single daily dose. These properties may
account, at least in part, for the documented
superiority of this agent over other renin–an-
giotensin system inhibitors in the prevention
and treatment of all stages of the cardiovascular
continuum from hypertension to the most sev-
ere forms of cardiovascular disease.
Recently updated European guidelines for
the management of arterial hypertension
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emphasize that initial therapy should comprise
a combination of two drugs, usually an ACE
inhibitor or ARB in combination with a calcium
channel blocker or thiazide-type diuretic,
preferably as a single-pill combination, based on
evidence from high-quality randomized con-
trolled trials or meta-analyses [56]. This strategy
has been implemented to ensure that target
blood pressure levels are achieved more rapidly
in a greater number of patients with improved
treatment adherence. It is well established that
regardless of antihypertensive therapy, much
greater treatment effects can be achieved by
adding a drug from another class than by dou-
bling the dose of the same drug [57]. It is also
known that combining drugs with comple-
mentary mechanisms of action can minimize
adverse events and improve tolerability relative
to the use of higher doses of one component. By
attenuating the deleterious effects of endothe-
lial dysfunction in addition to lowering blood
pressure, the early initiation of agents such as
ACE inhibitors and calcium channel blockers
could interrupt and slow the development of
endothelial dysfunction and progression to
clinical disease at all stages of the cardiovascular
continuum.
CONCLUSIONS
The involvement of endothelial dysfunction in
all stages of the cardiovascular continuum
makes it an important target for treatment. NO
is essential for endothelial function and its
production is increased both directly and indi-
rectly via inhibition of angiotensin II produc-
tion and reduced degradation of bradykinin by
the ACE inhibitors. Among the ACE inhibitors,
perindopril appears to have the greatest effects
on bradykinin and has demonstrated efficacy
on a number of markers of endothelial dys-
function including arterial stiffness and pro-
gression of atherosclerosis. Evidence from a
number of large, randomized controlled trials
supports the use of perindopril-based therapy
for the treatment of hypertension and for
reducing the risk of cardiovascular morbidity
and mortality in a wide range of patients across
the cardiovascular continuum.
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